
Insights Into Renal Cell Carcinoma (RCC)
Perspectives on drivers in treatment decisions in the management of RCC
Faculty Chair
Daniel J. George, MD
Duke Cancer Center
Faculty Chair
Ulka Vaishampayan, MD
Karmanos Cancer Center
Faculty Chair
Rana McKay, MD
UC San Diego Medical Center
Faculty Chair
Stephanie Berg, MD
Loyola University Medical Center
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center
Faculty Chair
David Braun, MD, PhD
Dana-Farber Cancer Center
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- National
More Information
- Virtual series
- Colorado, Iowa, Oregon
More Information
- Virtual series
- California, Arizona, Nevada, and New Mexico
More Information
- Virtual series
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
- Minnesota, Illinois
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Virtual series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region